CD274 and neoplasm: We applied SOS1i+MEKi alongside checkpoint immunotherapy combinations of agonistic aCD40, aPD-1, and aCTLA-4 with the rationale to: (i) reverse macrophage polarization toward an M1 phenotype, (ii) restore dendritic cell maturation and antigen presentation by utilizing agonistic aCD40, a myeloid activator (32, 50, 51), and (iii) maintain and further activate T cells inhibited by PD-L1 upregulation on tumor cells.